A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 177, Issue 1, 1998, Pages 48-56

  Feinberg, Judith E ^a   Hurwitz, Shelley ^b   Cooper, David ^c   Sattler, Fred R ^e   MacGregor, Rob Roy ^e   Powderly, William ^e   Holland, Gary N ^e   Griffiths, Paul D ^e   Pollard, Richard B ^e   Youle, Michael ^e   John Gill, M ^e   Holland, Fiona J ^e   Power, Maureen E ^e   Owens, Susan ^e   Coakley, Dion ^e   Fry, John ^d   Jacobson, Mark A ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GILEAD SCIENCES   (United States)

^d ABBOTT LABORATORIES   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VALACICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 6844258215     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513804     Document Type: Article

References (32)

1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988;108:585-94.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
3. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992;5:1069-74.
4. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. IV: visual outcomes. Ophthalmology 1994;101:1250-61.
5. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70-5.
6. Balfour HH, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
7. Mollison LC, Richards MJ, Johnson PDR, et al. High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis 1993;168:721-4.
8. Jacobson MA, Gallant J, Wang LH, et al. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 1994;38:1534-40.
9. Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61.
10. Cooper DA, Pehrson PO, Pederson C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. AIDS 1993;7:197-207.
11. Youle MS, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994;8:641-9.
12. Drew WL, Anderson R, Lang W, et al. Failure of high-dose acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J Acquir Immune Defic Syndr 1995;8:289-91.
13. Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1995;172:346-52.
14. Stein DS, Graham NMH, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Ann Intern Med 1994;121:100-8.
15. Ghazal P, Nelson JA. Interactions between cytomegalovirus immediateearly proteins and the long terminal repeat of human immunodeficiency virus. Med Virol 1993;3:47-55.
16. Lathey JL, Spector DU, Spector SA. Human cytomegalovirus-associated enhancement of human immunodeficiency virus type-1 production in monocyte-derived macrophages. Virology 1994;199:98-104.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972;135:185-206.
20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1140-54.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1977;35:549-56.
22. Griffiths PD, Feinberg JE, Fry J, et al. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. J Infect Dis 1998;177:57-64.
23. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic - microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997;76:369-80.
24. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-7.
25. Brosgart CL, Craig C, Hillman D, Louis TA, Alston B. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir of prophylaxis of CMV retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunosuppression [late-breaker abstract 10]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
26. Collier AC, Schoenfeld DA, Bourland D, et al. Prospective comparative study of acyclovir and zidovudine versus zidovudine alone in patients with AIDS. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections. Washington, DC: American Society for Microbiology, NIH, CDC 1995:383.
27. Stein DS. Acyclovir in human immunodeficiency virus patients [letter]. J Infect Dis 1996;173:504-5.
28. Heng MC, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;343:255-8.
29. Mole L, Ripich S, Margolis D, Holodniy M. Plasma HIV RNA levels are increased during active herpes simplex virus infection [abstract 239]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
30. Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982;73:182-5.
31. Peraldi MM, Maslo C, Desenclos JC, Raynal N, Rozenbaum W. Association between cytomegalovirus infection and thrombotic microangiopathy in HIV infected patients. J Am Soc Nephrol 1995;6:473-8.
32. Chulay JD, Bell AR. Long-term safety of valaciclovir for suppression of herpes simplex virus infection [abstract 105]. Clin Infect Dis 1996;23:879.